ArticleAnnals of hematology2026
Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy has changed the therapeutic landscape of relapsed/refractory multiple myeloma (RRMM). Despite the efficacy, these products have been associated with an adverse effect profile including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which require monitoring and early intervention. This is a retrospective cohort study using the National Readmission Database (NRD) aimed at evaluating hospital outcomes, economic burden, and readmission risks for ide-cel and cilta-cel in a real-world cohort of RRMM patients treated across various hospitals in the USA. During the study period,1291 RRMM patients receiving BCMA CAR-T cell therapy were identified in the United States. After excluding December admissions to allow for 30-day follow-up, 1180 patients were included in the final analysis. We found a 17% readmission rate within 30 days, with immune effector cell–related complications and infections constituting the most common causes of readmission. These findings highlight the significant clinical and economic burden of post-CAR-T care, despite the transformative impact of these therapies on outcomes for RRMM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.